Liquidia (LQDA) said Monday that United Therapeutics (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.
The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.
The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.
United Therapeutics did not immediately respond to a request for comment from MT Newswires.
Price: 15.46, Change: +0.20, Percent Change: +1.31
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。